MDASI Chronic Myeloid Leukemia Module
The MD Anderson Symptom Inventory for chronic myeloid leukemia (MDASI-CML) is a disease-specific MDASI module. Use the MDASI-CML to assess the severity of symptoms experienced by patients with chronic myeloid leukemia and the interference with daily living caused by these symptoms.
Along with the core MDASI¡¯s 13 symptom items and 6 interference items, the MDASI-CML also assesses 7 symptoms specific to chronic myeloid leukemia.
| Core MDASI Symptoms | CML Symptoms | MDASI Interference |
|---|---|---|
| Pain | Diarrhea (loose stools) | Relations with other people |
| Fatigue | Swelling | Enjoyment of life |
| Nausea | Rash or skin changes | Mood |
| Disturbed sleep | Muscle soreness or cramping | Walking |
| Distress (feeling upset) | Bruising or bleeding easily | Activity |
| Shortness of breath | Malaise | Work (including housework) |
| Difficulty remembering | Headache | |
| Lack of appetite | ||
| Drowsiness | ||
| Dry mouth | ||
| Sadness | ||
| Vomiting | ||
| Numbness/tingling |
Order the MDASI-CML
Use our convenient online form to order the MDASI-CML for use in your clinical research, clinical practice, funded and non-funded academic research, commercial research, or reproduction in educational materials or other publications.
MDASI-CML Features
- Purpose: To assess the severity of multiple chronic myeloid leukemia-related symptoms and the impact of these symptoms on daily functioning
- Population: Patients with symptoms caused by chronic myeloid leukemia and its treatment
- Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
- Method: Self-report or interview with research staff; paper-and-pencil or electronic data entry*
- Time required: Five minutes or less
- Scoring: Please see the MDASI User Guide
- Reliability: Cronbach alpha reliability ranges from 0.91 to 0.95
*Electronic data capture offers several benefits:
- Allows symptom monitoring when the patient is away from the hospital
- Is convenient for patients, who can choose web access, personalized patient portals, or smartphones to access questionnaires
- Minimizes missing data, especially in longitudinal studies
- Provides accurate, real-time symptom data at expected time points
- Generates immediate feedback, potentially allowing caregivers to address severe symptoms more effectively
MDASI-CML Language Versions
Click on a linked language to view a sample in PDF format.
Don't see a language you need? Contact us at symptomresearch@mdanderson.org.
| Psychometrically and Linguistically Validated | Linguistically Validated |
|---|---|
| English | Arabic |
| Bulgarian | |
| Chinese (Simplified) | |
| Chinese (Traditional) | |
| Czech | |
| Danish | |
| Dutch | |
| Finnish | |
| French | |
| German | |
| Greek | |
| Hebrew | |
| Hungarian | |
| Italian | |
| Japanese | |
| Korean | |
| Malay (in process) | |
| Polish | |
| Portuguese (Brazil) | |
| Portuguese (Portugal) | |
| Russian | |
| Serbian | |
| Spanish | |
| Swedish | |
| Thai |
MDASI User Guide
In response to the US Food and Drug Administration's 2009 guidance for the pharmaceutical industry on the use of patient-reported outcomes measures in medical product development to support labeling claims, we have prepared a MDASI User Guide to document the development and psychometric properties of the MDASI and its modules, including the MDASI-CML. The User Guide addresses the recommendations in the FDA guidance and establishes the MDASI's adequacy as a measure to support medical product claims.
Selected MDASI-CML References
Validation
Williams LA, Garcia-Gonzalez A, Ault P, et al. Blood 122(5):641-647, 2013.
Williams LA, Garcia-Gonzalez A, Ault P, et al. American Society of Clinical Oncology 47th Annual Meeting, Chicago IL, Jun 3-7, 2011. J Clin Oncol 29(15 Suppl), 2011; e19545.
Williams LA, Cortes JE, Ault P, Garcia-Gonzalez A, Williams JL, Cleeland CS. American Society of Hematology 2010 Annual Meeting, Orlando FL, Dec 4-7, 2010. Blood 116(21): 1065, 2010; 2573.
Cleeland CS, Mendoza TR, Wang XS, et al. Cancer 89:1634-1646, 2000.
Clinical Application
R¨¦a D, Boquimpani C, Mauro MJ, et al. Leukemia 37(5):1060-1067, 2023.
Schoenbeck KL, Flynn KE. Curr Hematol Malig Rep 16(6):491-499, 2021.
Bostan H, Toptas T, Tanrikulu FP, et al. Clin Lymphoma Myeloma Leuk 20(12):836-842, 2020.
Zulbaran-Rojas A, Lin HK, Shi Q, et al. Cancer Med 7(11):5457-5469, 2018.
Williams LA, Ault P, Garcia-Gonzalez A, et al. . American Society of Hematology 54th Annual Meeting and Exposition, Atlanta GA, Dec 8-11, 2012. Blood 118(21): 2012; 4260.
Williams LA, Jacobsen PB, Sailors MH, et al. Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) 2012 International Symposium on Supportive Care in Cancer, New York NY, Jun 28-30, 2012. Support Care Cancer 20(Suppl 1): S240, 2012; 1003.
Garcia-Gonzalez A, Ault P, Williams LA, et al. American Society of Clinical Oncology 48th Annual Meeting, Chicago IL, Jun 1-5, 2012; e19589.
Williams LA, Ault PS, Garcia-Gonzalez A, et al. American Society of Hematology 53rd Annual Meeting and Exposition, San Diego CA, Dec 10-13, 2011. Blood 118(21): 1356, 2011; 3138.
Every MDASI module contains:
all 13 core MDASI symptoms...
pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, difficulty remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness/tingling
...and all 6 MDASI interference items
general activity, mood, work, relations with others, walking, enjoyment of life
In our studies, a third of patients with CML reported having moderate-to-severe symptoms.
The MDASI-CML is a valid and reliable questionnaire that can help researchers and clinicians identify and assess these symptoms.
Loretta A. Williams, Ph.D., RN, AOCN
Associate Professor, Symptom?Research